Cerulean Pharma Inc.

Otsuka Pharmaceutical Co. Ltd. has entered into a definitive agreement to pay around $430m in cash for the private US antibody technology venture Visterra Inc. , in a step the major Japanese pharma

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

IN VITRO DIAGNOSTICS Financings Biocept Inc. Biocept Inc. (blood-based molecular diagnostics for solid tumors) netted $8.7mm through the sale of 4.3mm common shares at $2.15 (a slight discount) to

Financings Biopharma companies closed out 2016 with $9.6 billion in financing. ( See Exhibit 1. ) Not only was this a 30% increase over Q3's $7.4 billion, it was also the strongest quarter of the year